Exactly One Oxygen Bonded Directly To The Cyclopentanohydrophenanthrene Ring System (e.g., 3-hydroxycholanic Acids, Lithocholic Acids, Etc.) Patents (Class 552/552)
  • Patent number: 8586770
    Abstract: The invention relates to methods to manipulate stem cells in vivo and in vitro to treat, e.g., a condition where cell or tissue repair is needed.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: November 19, 2013
    Assignee: Harbor Therapeutics, Inc.
    Inventor: James M. Frincke
  • Publication number: 20130288318
    Abstract: The present invention relates to extracted lipid with high levels, for example 90% to 95% by weight, oleic acid. The present invention also provides genetically modified plants, particularly oilseeds such as safflower, which can used to produce the lipid. Furthermore, provided are methods for genotyping and selecting plants which can be used to produce the lipid.
    Type: Application
    Filed: April 24, 2013
    Publication date: October 31, 2013
    Applicants: Grains Research and Development Corporation, Commonwealth Scientific and Industrial Research Organisation
    Inventors: Craig Christopher WOOD, Qing LIU, Xue-Rong ZHOU, Allan GREEN, Surinder Pal SINGH, Shijiang CAO
  • Publication number: 20130261317
    Abstract: This invention relates generally to methods for preparing certain bile acids from non-mammalian sourced starting materials as well as to synthetic bile acids and compositions comprising such acids wherein the acids are characterized by a different C14 population than naturally occurring bile acids as well as being free from any mammalian pathogens. This invention is also directed to the synthesis of intermediates useful in the synthesis of such bile acids. Accordingly, the C ring of the steroidal scaffold is oxidized to provide a synthetic route and intermediates to DCA. This invention also provides synthetic methods for preparing deoxycholic acid or a salt thereof starting from aromatic steroids such as estrogen, equilenin, and derivatives thereof. This invention is also directed to intermediates such as 12-oxo or delta-9,11-ene steroids as well as novel processes for their preparation.
    Type: Application
    Filed: September 19, 2011
    Publication date: October 3, 2013
    Applicant: KYTHERA BIOPHARMACEUTICALS, INC.
    Inventors: Robert M. Moriarty, Photon Rao
  • Publication number: 20120127633
    Abstract: A metal electrolytic capacitor capable of quickly absorbing and immobilizing a belching vapor of a driving electrolyte and widely reducing leakage when an explosion-proof valve operates. An aluminum electrolytic capacitor body is configured by housing a capacitor element in a cylindrical aluminum case, a pair of leads extend from the capacitor body, an explosion-proof valve is formed on a top panel portion of the metal case, a cylindrical cap as a casing is attached from above to the capacitor body, a plurality of small openings are formed on a top panel portion (bottom portion) of the cap, and an absorbent or a mixture of an absorbent and a water molecular compound wrapped in a permeable fiber material, such as unwoven fabric and filter paper, is placed in a space between the cap and the top panel portion of the capacitor body.
    Type: Application
    Filed: June 2, 2010
    Publication date: May 24, 2012
    Inventors: Koichi Mori, Mitsuru Nozue, Minoru Yagi
  • Publication number: 20110257268
    Abstract: A process for the removal of sterols, specifically cholesterol, from a triglyceride oil, preferably a marine triglyceride oil, said process comprising contacting an oil with an adsorbent, specifically TRIS YL™, clay or a mixture thereof, heating the mixture to 100° C. to 210° C., preferably 150° C. to 170° C., preferably for a time period of greater than one minute and optionally at a pressure less than 133 Pa, preferably less than 1.33 Pa.
    Type: Application
    Filed: June 27, 2011
    Publication date: October 20, 2011
    Applicant: OCEAN NUTRITION CANADA LIMITED
    Inventor: Weijie Wang
  • Patent number: 7994351
    Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: August 9, 2011
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Achampeta Rathan Prasad, Roy A. Swaringen, Jr., John Gregory Reid, Robert M. Moriarty, Akhila Kumar Sahoo
  • Publication number: 20110136773
    Abstract: The invention generally refers to pharmaceutical uses of lanosta-8,24-dien-3-ols, a family of tetracyclic terpenols, as anti-inflammatory, anticancerigenous and analgesic agents via the inhibition of the disordered activation of serine-threonine protein kinases, particularly PKC.
    Type: Application
    Filed: August 5, 2008
    Publication date: June 9, 2011
    Applicant: AMAZONIA FITOMEDICAMENTOS LTDA
    Inventors: Luiz Francisco Pianowski, Joao Batista Calixto, Paulo Cesar Leal, Claudio Paulino Chaves
  • Patent number: 7932243
    Abstract: The present disclosure relates to methods and compositions to offset, ameliorate and/or alleviate one or more unwanted and/or adverse gastrointestinal effects. For example, in some embodiments, the present disclosure relates to compositions that include a bile acid, a carbohydrate and/or a pharmaceutical compound, wherein the pharmaceutical is associated with an adverse gastrointestinal effect in a subject (e.g., mammal or human). Non-limiting examples of pharmaceutical compounds may include a nonsteroidal anti-inflammatory drug, a gastric irritating drug (e.g., an antibiotic, an adrenal cortocoid steroid and an anti-cancer drug) and combinations thereof. The disclosure further relates to methods of ameliorating or eliminating at least one adverse gastrointestinal effects of a composition, comprising administering to a subject an aqueous solution comprising a bile acid and a carbohydrate.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: April 26, 2011
    Inventor: Seo Hong Yoo
  • Publication number: 20110087037
    Abstract: Novel 3?-hydroxy-?5-steroid analogs possessing a contracted cyclopentane B-ring provide good inhibitory activity against Mycobacterium tuberculosis. The 5(6?7)abeo-sterol nucleus present in compounds of the invention represents a novel scaffold for the development of new antitubercular agents.
    Type: Application
    Filed: October 31, 2008
    Publication date: April 14, 2011
    Applicant: OFFICE OF INTELLECTUAL PROPERTY AND TECHNOLOGY VIC
    Inventors: Abimael D. Rodriguez-Pierluissi, Xiaomei Wei
  • Patent number: 7598235
    Abstract: This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: October 6, 2009
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Mark A. Gallop
  • Patent number: 7501403
    Abstract: The present invention relates to the use of a bile acid or bile salt fatty acid conjugate of general formula II W-X-G in which G is a bile acid or bile salt radical, which, if desired, is conjugated in position 24 with a suitable amino acid, W stands for one or two fatty acid radicals having 14-22 carbon atoms and X stands for a suitable bonding member or for a direct C?C bond between said bile acid or bile salt radical and the fatty acid(s) or of a pharmaceutical composition comprising same for the reduction of Cholesterol in blood, for the treatment of Fatty Liver, Hyperglycemia and Diabetes.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: March 10, 2009
    Assignee: Galmed International Limited
    Inventor: Tuvia Gilat
  • Publication number: 20090061358
    Abstract: Photoacid generators generate sulfonic acids of formula (1a) or (1c) upon exposure to high-energy radiation. R1—COOCH(CF3)CF2SO3+H+??(1a) R1—O—COOCH(CF3)CF2SO3?H+??(1c) R1 is a C20-C50 hydrocarbon group having a steroid structure. The photoacid generators are compatible with resins and can control acid diffusion and are thus suited for use in chemically amplified resist compositions.
    Type: Application
    Filed: September 4, 2008
    Publication date: March 5, 2009
    Inventors: Masaki OHASHI, Youichi Ohsawa, Takeru Watanabe, Takeshi Kinsho
  • Patent number: 7381566
    Abstract: A method for preparing organic nanotubules in an aqueous medium including preparing a basic solution with a pH from 10 to 14, adding an organic compound of the formula: wherein R1 is a C17-C20 polycyclic radical with fused rings optionally including alkyl substituents, R2 is a C3-C20 linear or branched alkylene group, and R3 represents a hydrogen atom, a C1-C20 alkyl or C6-C30 aromatic group, and submitting the solution to stirring for sufficient time in order to form stable tubules of the organic compound in the solution; and nanotubules prepared by the method.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: June 3, 2008
    Assignees: Commissariat a l'Energie Atomique, Centre National de la Recherche Scientifique
    Inventor: Pierre Terech
  • Patent number: 7122533
    Abstract: The present invention relates to methods, compounds and compositions for inhibiting effective binding of a chemokine to its cellular receptor. In one form of the invention, a method includes contacting a cellular population with an effective amount of cosalane or an analog thereof. The invention further relates to methods, compounds and compositions for treating inflammatory diseases. In one form, a method includes administering to a patient a therapeutically effective amount of cosalane or an analog thereof.
    Type: Grant
    Filed: May 13, 2003
    Date of Patent: October 17, 2006
    Assignees: The United States of America as represented by the Department of Health and Human Services, Purdue Research Foundation
    Inventors: Mark S. Cushman, O. M. Zack Howard
  • Patent number: 6900192
    Abstract: This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: May 31, 2005
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Mark A. Gallop, Cindy X. Zhou
  • Patent number: 6881730
    Abstract: Compounds of Formula (I) in which: R1 and R2, which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group; R3 represents a methyl group having ?- or ?-configuration; R4 represents a hydrogen atom or an etherifying or esterifying group; R5 represents a hydrogen atom, a hydroxyl group or a lower alkoxy group; X represents a group OR4, wherein R4 is as defined above, or a group NR6R7 wherein R6 represents a hydrogen atom, an aliphatic or araliphatic organic group, or an acyl group comprising an aliphatic, araliphatic or aryl organic group linked to the nitrogen atom by way of a carbonyl group; and R7 is a hydrogen atom or a lower alkyl group; Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and the dotted lines signify that double bonds may be present at the 16(17)-position and/or either at the 6(7)- and 8(9)-positions or at the 7(8)-position exhibit potent effects on modulation of
    Type: Grant
    Filed: May 11, 2003
    Date of Patent: April 19, 2005
    Assignee: Research Institute for Medicine & Chemistry, Inc.
    Inventors: Robert Henry Hesse, Sundara Katugam Srinivasasetty Setty, Malathi Ramgopal, Sanga Kugabalnsooriar
  • Patent number: 6770414
    Abstract: The present invention provides an additive for a photoresist composition for a resist flow process. A compound of following Formula 1 having low glass transition temperature is added to a photoresist composition containing a polymer which is not suitable for the resist flow process due to its high glass transition temperature, thus improving a flow property of the photoresist composition. As a result, the photoresist composition comprising an additive of Formula 1 can be used for the resist flow process. wherein, A, B, R and R′ are as defined in the specification of the invention.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: August 3, 2004
    Assignee: Hynix Semiconductor Inc.
    Inventors: Min Ho Jung, Sung Eun Hong, Jae Chang Jung, Geun Su Lee, Ki Ho Baik
  • Patent number: 6706701
    Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: March 16, 2004
    Assignees: Inflazyme Pharmaceuticals Ltd., University of British Columbia, University of Alberta
    Inventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
  • Patent number: 6653492
    Abstract: Certain bile acids find use in the pharmaceutical industry. In view of the wide distribution of serious diseases such as HIV, AIDS and Bovine Spongiform Encephalopathy (BSE) it is desirable to avoid—as far as practicable—to have any components of animal origin in medicaments in order to eliminate any danger of infection. The present invention relates to a method of providing bile acids from non-animal starting materials.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: November 25, 2003
    Assignee: Novo Nordick A/S
    Inventor: Peter Faarup
  • Patent number: 6635774
    Abstract: The present invention provides a method for the direct esterification of stanols and sterols with fatty acids to form stanol/sterol-esters. The method provides a synthetic route that is amenable to large scale production of the esters in high yields. A preferred embodiment employs a food grade process free of organic solvents or mineral acids, does not produce or use non-food grade products and is substantially free of the use of a catalyst.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: October 21, 2003
    Assignee: McNeil-PPC, Inc.
    Inventors: Allan Roden, James L. Williams, Ruey Bruce, Frank Detrano, Marie H. Boyer
  • Patent number: 6624155
    Abstract: The present invention provides hybrid molecules and methods of synthesizing such hybrid molecules from a cholinergic agent and a bile acid. The hybrid molecules function as cholinergic agents and may be either cholinergic agonists or cholinergic antagonists. Further disclosed herein are compositions comprising hybrid cholinergic agents and methods of making such compositions. Methods of treating a patient having a cholinergic disorder are also disclosed.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: September 23, 2003
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Jean-Pierre Raufman, Piotr Zimniak, Kunrong Cheng
  • Patent number: 6624156
    Abstract: The present invention provides hybrid molecules and methods of synthesizing such hybrid molecules from a cholinergic agent and a bile acid. The hybrid molecules function as cholinergic agents and may be either cholinergic agonists or cholinergic antagonists. Further disclosed herein are compositions comprising hybrid cholinergic agents and methods of making such compositions. Methods of treating a patient having a cholinergic disorder are also disclosed.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: September 23, 2003
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Jean-Pierre Raufman, Piotr Zimniak, Kunrong Cheng
  • Patent number: 6528501
    Abstract: The invention relates to 22S hydroxycholesta-8, 14-diene derivatives having general formula (I) wherein R1 is OR, OSO3H or —NOR; with R being H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is independently hydrogen or (C1-6)alkyl; R4 is hydrogen, (C1-6)alkyl or (C1-6)acyl; R5 is hydrogen; or R5 designates, together with R6, an additional bond between the carbon atoms at which R5 and R6 are placed; R6 is hydrogen, hydroxy or halogen, or R6 designates, together with R5, an additional bond between the carbon atoms at which R6 and R5 are placed; each or R7 and R8 is independently hydrogen or (C1-4)alkyl, optionally substituted with OH, (C1-4)alkoxy, or halogen; or a pharmaceutically acceptable salt thereof. The compounds of the invention have meiosis activating activity and can be used for the control of fertility.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: March 4, 2003
    Assignee: Akzo Nobel N.V.
    Inventors: Dirk D. Leysen, Jaap J. van der Louw, Robert Gerard Jules Marie Hanssen, A. Anja Wiersma
  • Patent number: 6497987
    Abstract: A photosensitive compound, and a chemically amplified photoresist composition containing the photosensitive compound, maintain transparency even when exposed to a short-wavelength light source of 193 nm or below, and exhibit improved adhesion to an underlying film or substrate, improved wettability to a developing solution and improved resistance to dry etching. The photosensitive compound includes a carboxylic acid protected with a protective group capable of being deprotected with an acid and has a hydroxy at position No. 3 substituted with a hydrophillic aliphatic compound or a hydrophillic alicyclic compound.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: December 24, 2002
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Hyun-woo Kim, Sook Lee, Sang-gyun Woo
  • Publication number: 20020183531
    Abstract: Certain bile acids find use in the pharmaceutical industry. In view of the wide distribution of serious diseases such as HIV, AIDS and Bovine Spongiform Encephalopathy (BSE) it is desirable to avoid—as far as practicable—to have any components of animal origin in medicaments in order to eliminate any danger of infection. The present invention relates to a method of providing bile acids from non-animal starting materials.
    Type: Application
    Filed: May 1, 2002
    Publication date: December 5, 2002
    Inventor: Peter Faarup
  • Patent number: 6437156
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor cholane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: August 20, 2002
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
  • Patent number: 6388108
    Abstract: Newly isolated aminosterol compounds and pharmaceutical compositions based on the aminosterol compounds are described. Methods for the treatment of various disorders, for example, a microbial infection, are also described.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: May 14, 2002
    Assignee: Genaera Corporation
    Inventors: Meena Rao, Binyamin Feibush, William Kinney, Michael Zasloff, Lincoln Noecker
  • Publication number: 20020025951
    Abstract: A compound having the general formula: 1
    Type: Application
    Filed: May 24, 1999
    Publication date: February 28, 2002
    Inventors: HYUN K. KIM, RICHARD P. BLYE, PEMMARAJU N. RAO, JAMES W. CESSAC, CARMIE K. ACOSTA
  • Patent number: 6177420
    Abstract: The invention relates to 20-aralkyl-5&agr;-pregnane derivative having general formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is (H,OR), (H,OSO3H) or NOR; R is H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is independently hydrogen or (C1-6)alkyl; X is a straight chain divalent C1-8 hydrocarbon radical, optionally comprising a double or a triple bond; or X is —(CH2)m—CR7R8—; m=0-4; at least one of R7 and R8 is (C1-4)alkyl, hydroxy, (C1-4)alkoxy or halogen; the other, if present, being hydrogen; or R7 and R8 together represent O or NOR′; R′ is H, (C1-6)alkyl or (C1-6)acyl; each of R4, R5 and R6 is independently hydrogen, hydroxy, (C1-4)alkoxy, halogen, NR9, R10 or (C1-4)alkyl, optionally substituted by hydroxy, alkoxy, halogen or oxo; each of R9 and R10 is independently hydrogen or (C1-4)alkyl; and the dotted lines indicate a &Dgr;7 or a &Dgr;8 double bond, or a pair of conjugated double bonds selected from &Dgr;7,14, &Dgr;8,14 and
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: January 23, 2001
    Assignee: Akzo Nobel N.V.
    Inventors: Johannes Antonius Joseph Leemhuis, Jaap van der Louw, Marinus Bernard Groen
  • Patent number: 6080735
    Abstract: This invention is relating to new estra-1,3,5(10)-trien-sulfamates carrying at the 3-position an R--SO.sub.2 --O--group, with R being an R.sup.1 R.sup.2 N--group in which R.sup.1 and R.sup.2, independently of each other, represent a hydrogen atom, an alkyl residue with 1-5 C atoms or, together with the N atom, a polymethylene-imino residue with 4-6 C atoms or a morpholino residue.The compounds, according to this invention, are suitable for hormonal contraception and climacteric hormone replacement therapy (HRT) as well as for treatment of gynecological and andrological diseases. Hence, only low hepatic estrogenicity is exhibited by the compounds according to this invention.Also described are processes for preparation of the compounds according to this invention and for preparation of pharmaceutical compositions.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: June 27, 2000
    Assignee: Jenapharm GmbH & Co. KG
    Inventors: Sigfrid Schwarz, Walter Elger, Hans-Joachim Siemann, deceased, by Margit Lucas, heir, by Frank Siemann, heir, Gudrun Reddersen, Birgitt Schneider
  • Patent number: 6046186
    Abstract: Novel compounds useful as inhibitors of estrone sulfatase are provided. The compounds have the structural formula (I) wherein r1 is an optional double bond, R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen and lower alky, or together form a cyclic substituent (II) ##STR1## wherein Q is NH, O or CH.sub.2, and the other various substituents are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat estrogen-dependent disorders are provided as well.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: April 4, 2000
    Assignee: SRI International
    Inventors: Masato Tanabe, Richard H. Peters, Wan-Ru Chao, Kazuhiko Shigeno
  • Patent number: 6040468
    Abstract: 16.alpha., 17.alpha.-dialkylated steroids are prepared by reacting a 16.alpha.-alkyl-17(20)-enyl-20-silyl ether with an alkylating agent and an enol silyl ether cleaving agent in a suitable solvent.
    Type: Grant
    Filed: November 5, 1998
    Date of Patent: March 21, 2000
    Assignee: Alcon Laboratories, Inc.
    Inventor: Raymond E. Conrow
  • Patent number: 5847173
    Abstract: 21-norvitamin D.sub.3 analogs in which the methyl group normally attached to the side chain at carbon 20 has been replaced by a hydrogen atom. The compounds are characterized by a marked intestinal calcium transport activity while exhibiting much lower activity than 1.alpha.,25-dihydroxyvitamin D.sub.3 in their ability to mobilize calcium from bone. Because of their preferential calemic activity, these compounds would be useful for the treatment of diseases where bone formation is desired, such as osteodystrophy. Novel intermediates formed during the synthesis of the end products are also disclosed.
    Type: Grant
    Filed: November 18, 1996
    Date of Patent: December 8, 1998
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Jerzy Wicha
  • Patent number: 5792759
    Abstract: Novel 17-hydroxyiminoalkyl and 17-hydroxyiminomethylalkenyl steroids of the general formula (I) ##STR1## where A, R.sup.1 and R.sup.2 are defined in the specification are disclosed. The compounds have cardiovascular activity. Pharmaceutical compositions containing compounds of formula (I) are also disclosed for the treatment of heart failure and hypertension.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: August 11, 1998
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Luisa Quadri, Alberto Cerri, Patrizia Ferrari, Maria Pia Zappavigna
  • Patent number: 5723455
    Abstract: Novel antiandrogenic agents are provided. An exemplary group of compounds has the structural formula (I) ##STR1## wherein R.sup.1 through R.sup.10, a and b are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat androgen-related clinical conditions are provided, as are methods and compositions for using the compounds as contraceptive agents.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: March 3, 1998
    Assignee: SRI International
    Inventors: Masato Tanabe, Wan-Ru Chao, Wesley K. M. Chong, David F. Crowe
  • Patent number: 5705495
    Abstract: The invention relates to new sulfamate derivatives of 1,3,5(10)-estratriene derivatives of the general formula I ##STR1## wherein the 3-sulfamate moiety is acylated, sulfonated or amidosulfonated. Furthermore, methods for the production of the compound and pharmaceutical preparations containing this compound are described. The compounds according to the invention have an estrogenic effect.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: January 6, 1998
    Assignee: Jenapharm GmbH & Co. KG.
    Inventors: Sigfrid Schwarz, Walter Elger, Gudrun Reddersen, Birgitt Schneider, Ina Thieme, Margit Richter
  • Patent number: 5637691
    Abstract: Compounds having a broad range of antimicrobial activity generally have a structure including asteroid nucleus with a cationic, preferably polyamine, side chain (X) and an anionic side chain (Y). The invention is also directed to compounds of the Formula III: ##STR1## preferably where the steroid ring nucleus is saturated; the steroid ring substituent Z.sub.5 is .alpha.-H; one Z.sub.7 is .beta.-H and the other is .alpha.-H or .alpha.-OH; both substituents Z.sub.12 are hydrogen; X' is a polyamine side chain of the formula --NH--(CH.sub.2).sub.p --NH--(CH.sub.2).sub.q --N(R.sup.II)(R.sup.III) where p and q are each independently 3 or 4, and R.sup.II and R.sup.III are each independently hydrogen or methyl; R' is methyl; and Y' is (C.sub.1 -C.sub.10)-alkyl substituted with a group such as --CO.sub.2 H or --SO.sub.3 H.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: June 10, 1997
    Assignee: Magainin Pharmaceuticals, Inc.
    Inventors: Leah L. Frye, Michael A. Zasloff, William A. Kinney, Robert Moriarty
  • Patent number: 5618806
    Abstract: Invented are 17.alpha. and 17.beta.-substituted acyl-3-carboxy aromatic A ring analogues of steroidal synthetic compounds. Representative of such compounds include the following ##STR1## wherein Z is .alpha. or .beta. ##STR2## in which A is absent or present as a linear or branched, saturated or unsaturated hydrocarbon chain containing from 1-6 carbon atoms and R isa) a linear or branched, saturated or unsaturated hydrocarbon chain containing 1-12 carbon atoms substituted with one or more substituents selected from the group consisting of: --OC.sub.6 -C.sub.12 aryl, --OC.sub.1 -C.sub.4 alkyl, halogen, carboxy and --S(O).sub.n .sup.R.sup.7, where n is 0-2 and R.sup.7 is hydrogen or C.sub.1-4 alkyl;b) C.sub.3 -C.sub.8 nonaromatic, unsaturated or saturated, cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of:--OC.sub.6 -C.sub.12 aryl, --(CH.sub.2).sub.m OH, --OC.sub.1 -C.sub.4 alkyl, C.sub.6 -C.sub.12 aryl, C.sub.1 -C.sub.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: April 8, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Dennis A. Holt, Mark A. Levy
  • Patent number: 5561124
    Abstract: The invention relates to substituted 17.alpha.-acyl steroidal 5.alpha.-reductase inhibiting compounds. The invention also relates to pharmaceutical compositions containing these compounds and their use for reducing prostate size and treating prostate adenocarcinoma. Further, the invention describes a process for making these compounds by heating the corresponding substituted 17.beta.-acyl steroid in a solvent, such as ethylene glycol or dimethyl sulfoxide (DMSO), in a base, such as sodium or potassium hydroxide.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: October 1, 1996
    Inventor: Robert L. Webb
  • Patent number: 5559258
    Abstract: Ethylenically unsaturated bile acid derivatives of the formula IG--X--A Iin which G, X and A have the meanings indicated, are described. They are suitable for the preparation of polymeric bile acid derivatives. Bile acid derivatives of the formula IVaG--X' IVain which G and X' have the meanings indicated, are also described. They are useful synthesis components for the preparation of pharmaceuticals.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: September 24, 1996
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Alfons Enhsen, Heiner Glombik, Stefan M ullner, G unther Wess
  • Patent number: 5541348
    Abstract: Novel bile acids according to the general formula ##STR1## wherein R.sub.1 represents a hydroxyl group, R.sub.2 and R.sub.3 both represent a hydrogen or a hydroxyl group, or R.sub.2 represents a hydroxyl group or a .beta. hydroxyl group and R.sub.3 represents a hydrogen or R.sub.3 represents a hydroxyl group and R.sub.2 represents a hydrogen, and R.sub.4 represents a (CH.sub.2).sub.n R.sub.5 wherein n is from 1 to 6, and R.sub.5 represents --0--PO(OH).sub.2, --CH(OH)COOH, a nitrogen containing saturated heterocyclic ring group, NR.sub.6 R.sub.7, wherein R.sub.6 and R.sub.7 are the same or different and each represent hydrogen or a C.sub.1 -C.sub.10 alkyl group or CO--R.sub.8 wherein R.sub.8 represents an amino acid moiety, R-phenylglycine, 12-aminododecanoic acid or 4-aminohippuric acid are synthesized from cholic, deoxycholic, chenodeoxycholic, ursodeoxycholic and lithocholic acids and iodo-derivatives thereof by known processes and/or by novel processes according to the present invention.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: July 30, 1996
    Assignee: National Research Council of Canada
    Inventors: Prabhat Ayra, Graham W. Burton
  • Patent number: 5523428
    Abstract: A process for the production of 1-methyl-3-keto-.DELTA..sup.1,4 steroids of general formula I ##STR1## in which St symbolizes the radical of asteroid molecule, where a 3-keto-.DELTA..sup.1,4 steroid of general formula II ##STR2## in which St has the above-mentioned meaning, is reacted in an inert solvent in the presence of a nickel salt soluble therein with an organometallic compound of formula III, IV or V ##STR3## where X, Y.sub.1, Y.sub.2, Y.sub.3, Z.sub.1 and Z.sub.2 are as defined in the specification.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: June 4, 1996
    Assignee: Schering Aktiengesellschaft
    Inventors: Jurgen Westermann, Klaus Nickisch, Annette Prelle
  • Patent number: 5496813
    Abstract: There are described spontaneously dispersible agents containing sterolester and/or sterolphosphor compounds having a pronounced antitumour activity. Novel sterolesters and sterolphosphor compounds, their use for treating tumors, and processes for their preparation are disclosed.
    Type: Grant
    Filed: August 13, 1992
    Date of Patent: March 5, 1996
    Assignee: Marigen S.A.
    Inventors: Carl Eugster, Conrad H. Eugster, Walter Haldemann, Giorgio Rivara
  • Patent number: 5473087
    Abstract: Mixtures of compounds of ##STR1## or a mixture of the latter and a compound of the formula ##STR2## which are useful intermediates for the preparation 20-keto-21(S)-hydroxy steroids.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: December 5, 1995
    Assignee: Roussel-Uclaf
    Inventors: Jean Buendia, Jean-Yves Godard, Philippe Mackiewicz, Christian Richard
  • Patent number: 5399685
    Abstract: A process for the preparation of a compound of the formula ##STR1## wherein R.sub.1 is alkyl of 1 to 3 carbon atoms, R.sub.2 is alkyl of 1 to 12 carbon atoms, R.sub.3 is alkyl of 1 to 4 carbon atoms comprising reacting a compound of the formula ##STR2## wherein R.sub.4 is a remainder of an easily cleavable ether, K is a protected ketone function in the form of ketal, thioketal or mixed ketal and R.sub.1 has the above definition with a magnesium organic compound reagent of the formulaHalMg--CH.sub.2 --R.sub.2 Awherein Hal is a halogen and R.sub.2 is defined as above to obtain a compound of the formula ##STR3## wherein R.sub.1, R.sub.2 and K are defined as above, reacting the latter with an acylation agent to obtain a compound of the formula ##STR4## wherein R.sub.5 is alkyl of 1 to 6 carbon atoms or aryl of 6 to 10 carbon atoms and R.sub.1, R.sub.2 and K are defined as above, reacting the latter with an appropriate alkylation agent to obtain a compound of the formula ##STR5## wherein R.sub.1, R.sub.2, R.sub.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: March 21, 1995
    Assignee: Roussel-Uclaf
    Inventors: Jean Buendia, Veronique Crocq, Christian Masson, Denis Prat, Michel Vivat
  • Patent number: 5384419
    Abstract: An improved process for the preparation of 20-keto-21(S)-hydroxy steroids of the Formula ##STR1## wherein R.sub.1 is alkyl of 1 to 3 carbon atoms, R.sub.2 is alkyl of 1 to 12 carbon atoms, and R.sub.3 is alkyl of 1 to 4 carbon atoms and novel intermediates therefrom.
    Type: Grant
    Filed: June 2, 1993
    Date of Patent: January 24, 1995
    Assignee: Roussel-Uclaf
    Inventors: Jean Buendia, Jean-Yves Godard, Philippe Mackiewicz, Christian Richard
  • Patent number: 5352781
    Abstract: The process of the invention comprises reacting a C-22-halo-23,24-bisnorsteroid or C-22-halo-23,24-bisnor-9,10-secosteroid with a nickel complex of an electron withdrawing alkene of the formula ##STR1## wherein R.sub.1 is hydrogen, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyl or unsubstituted or substituted lower alkyl, and R.sub.2 is hydroxyl, lower alkoxy, or unsubstituted or substituted lower alkyl, to yield a C-25 or C-26 precursor of the formula ##STR2## which is appropriately functionalized for conversion into the corresponding steroid or secosteroid by treatment as hereinafter described.
    Type: Grant
    Filed: March 19, 1993
    Date of Patent: October 4, 1994
    Assignee: Hoffmann-La Roche Inc.
    Inventors: George P. Yiannikouros, Percy S. Manchand
  • Patent number: 5319115
    Abstract: This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3.alpha.-hydroxy,3.beta.-substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereoselectively into a 3(R)-pregnan-3-spiro-2'oxirane-20-one intermediate. This intermediate can then be converted regioselectively by a second set of reactions to the 3.alpha.-hydroxy,3.beta.-substituted-20-one form, which can be further modified at the 20-keto position.Through this method, each ketone group is independently treated. By modifying the ketones one at a time, one can obtain the desired stereo-specificity at each site.
    Type: Grant
    Filed: March 4, 1992
    Date of Patent: June 7, 1994
    Assignee: Cocensys Inc.
    Inventors: Hasan Tahir, Michael Bolger, Richard Buswell, Richard Gabriel, Jay Stearns
  • Patent number: 5272140
    Abstract: The invention relates to 11-aryl steroid derivatives, having the structure ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as described in the specificationand to processes for their preparation and to pharmaceuticals comprising these compounds.These compounds exhibit a strong anti-progestinic activity and a weak or non-existent anti-glucocorticoid activity.
    Type: Grant
    Filed: February 27, 1990
    Date of Patent: December 21, 1993
    Assignee: Akzo N.V.
    Inventor: Hubert J. J. Loozen
  • Patent number: 5140106
    Abstract: A process for the production of 3-deoxy-4-ene steroids of the general formula I ##STR1## is described, in which R.sub.1, R.sub.2 and R.sub.3 mean a hydrogen atom or a methyl group,R.sub.4 represents a lower alkyl group, a phenyl group or a free, esterified or etherified hydroxy group,R.sub.5 symbolizes a hydrogen atom, a vinyl group or the grouping --C.tbd.CR.sub.6 with R.sub.6 meaning a hydrogen atom, an alkyl group with a maximum of 4 carbon atoms or a halogen atom,X represents a methylene group, a fluoromethylene group, an ethylidene group or a vinylidene group,Y and U represent a methylene group or an ethylidene group andZ symbolizes a methylene group, an ethylidene group, a vinylidene group, a chloromethylene group or a hydroxymethylene group and in which the bonds represent three single bonds or one double bond and two single bonds or a conjugated double bond.
    Type: Grant
    Filed: January 17, 1991
    Date of Patent: August 18, 1992
    Assignee: Schering Aktiengesellschaft
    Inventors: Ekkehard Winterfeldt, Ulf Tilstamm, Helmut Hofmeister, Henry Laurent